Patients with advanced non-small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real-world data analysis

被引:10
作者
Chang, Nijia [1 ]
Duan, Jingjing [1 ]
Wang, Lingxiong [2 ]
Dong, Zhouhuan [3 ]
Liu, Zhefeng [2 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, Chinese Peoples Liberat Army Med Sch, Beijing 100853, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, 28 Fuxing Rd, Beijing 100853, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Dept Pathol, Beijing 100853, Peoples R China
关键词
non-small cell lung cancer; osimertinib; resistance mechanism; ACQUIRED-RESISTANCE; RECEPTOR GENE; AZD9291; NSCLC; AMPLIFICATION; MECHANISM; SENSITIVITY; GEFITINIB; EMERGENCE; TUMORS;
D O I
10.3892/ol.2020.11801
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study aimed to investigate the clinical characteristics and outcomes of patients with advanced non-small cell lung cancer (NSCLC) treated with osimertinib, and focused on the resistance mechanism to osimertinib in a real-world setting. Data from 128 patients with advanced NSCLC who were treated with osimertinib between March 2015 and November 2018 at the Chinese People's Liberation Army General Hospital (Beijing, China) were retrospectively collected, and the associations between mutation types and survival were analysed. In patients treated with osimertinib, the objective response rate reached 60.9% (78/128) and the disease control rate reached 81.3% (104/128), with a median progression-free survival (PFS) time of 12.2 months. A number of complex mutations were identified in the re-analysis after the development of osimertinib resistance, including TP53, KRAS and PIK3CA mutations, epidermal growth factor receptor (EGFR) and MYC amplifications, and mutations associated with SCLC transformation, demonstrating that these mutations may account for osimertinib resistance. The median PFS time for patients with the EGFR T790M mutation (n=41) was significantly longer than that for patients with the T790M mutation and the aforementioned complex mutations (n=13) (16.7 vs. 10.8 months; P=0.001). Patients with a single EGFR mutation (n=87) had a longer median PFS time than those with an EGFR mutation and complex mutations (n=24) (14.63 vs. 6.63 months; P<0.0001). In conclusion, the present study analysed the effects of osimertinib in patients with advanced NSCLC with EGFR mutations, particularly T790M mutations. The results indicated that the efficacy of osimertinib was weakened when patients had complex mutations, suggesting that complex mutations may be responsible for resistance to osimertinib.
引用
收藏
页码:2266 / 2272
页数:7
相关论文
共 50 条
[41]   The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancer [J].
Karachaliou, Niki ;
Angel Molina-Vila, Miguel ;
Rosell, Rafael .
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2015, 9 (03) :241-244
[42]   Current treatment landscape for patients with non-small cell lung cancer with common EGFR mutations [J].
Miyata, Masayuki ;
Hayashi, Hidetoshi .
RESPIRATORY INVESTIGATION, 2025, 63 (04) :576-584
[43]   Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non-small-cell lung cancer harboring EGFR mutations: Results from a real-world study in South Korea [J].
Kim, Taeyun ;
Jang, Tae Won ;
Choi, Chang Min ;
Kim, Mi-Hyun ;
Lee, Sung Yong ;
Park, Cheol-Kyu ;
Chang, Yoon Soo ;
Lee, Kye Young ;
Kim, Seung Joon ;
Yang, Sei Hoon ;
Ryu, Jeong Seon ;
Lee, Jeong Eun ;
Lee, Shin Yup ;
Park, Chan Kwon ;
Lee, Sang Hoon ;
Jang, Seung Hun ;
Yoon, Seong Hoon .
CANCER MEDICINE, 2021, 10 (17) :5809-5822
[44]   Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta [J].
Cheung, Winson Y. ;
Carbonell, Chantelle ;
Navani, Vishal ;
Sangha, Randeep S. ;
Ewara, Emmanuel M. ;
Elia-Pacitti, Julia ;
Iczkovitz, Sandra ;
Jarada, Tamer N. ;
Warkentin, Matthew T. .
CURRENT ONCOLOGY, 2024, 31 (08) :4382-4396
[45]   A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations [J].
Huanlan Sa ;
Yan Shi ;
Chunxia Ding ;
Kewei Ma .
Journal of Cancer Research and Clinical Oncology, 2023, 149 :7729-7742
[46]   A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study [J].
Xin Tang ;
Yuan Li ;
Wen-lei Qian ;
Wei-feng Yan ;
Tong Pang ;
You-ling Gong ;
Zhi-gang Yang .
Journal of Cancer Research and Clinical Oncology, 2022, 148 :2475-2486
[47]   First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study [J].
Tsukita, Yoko ;
Inoue, Akira .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (05) :405-410
[48]   Complex EGFR mutations in non-small cell lung cancer: a distinct entity? [J].
Bienkowski, Michal ;
Dziadziuszko, Rafal ;
Jassem, Jacek .
JOURNAL OF THORACIC DISEASE, 2022,
[49]   Real World Analysis Afatinib as a First Line Treatment Patients with Advanced Stage Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations [J].
Pham, L. V. ;
Nguyen, H. M. ;
Le, A. T. .
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) :S336-S336
[50]   Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea [J].
Byeon, Seonggyu ;
Kim, Youjin ;
Lim, Sung Won ;
Cho, Jang Ho ;
Park, Sehoon ;
Lee, Jiyun ;
Sun, Jong-Mu ;
Choi, Yoon-La ;
Lee, Se-Hoon ;
Ahn, Jin Seok ;
Park, Keunchil ;
Ahn, Myung-Ju .
CANCER RESEARCH AND TREATMENT, 2019, 51 (02) :623-631